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Abstract
Objective—To evaluate the use of the short
form 36 (SF36) as a measure of health
related quality of life of patients with end
stage renal failure, document the results,
and investigate factors, including mode of
treatment, which may influence it.
Design—Cross sectional survey of pa-
tients with end stage renal failure, with the
standard United Kingdom version of the
SF36 supplemented by specific questions
for end stage renal failure.
Setting—A teaching hospital renal unit.
Subjects and methods—660 patients
treated at the SheYeld Kidney Institute by
haemodialysis, peritoneal dialysis, and
transplantation. Internal consistency, per-
centage of maximal or minimal responses,
SF36 scores, eVect sizes, correlations
between independent predictor variables
and individual dimension scores of the
SF36. Multiple regression analysis of the
SF36 scores for the physical functioning,
vitality, and mental health dimensions
against treatment, age, risk (comorbidity)
score, and other independent variables.
Results—A high response rate was
achieved. Internal consistency was good.
There were no floor or ceiling eVects other
than for the two “role” dimensions. Over-
all health related quality of life was poor
compared with the general population.
Having a functioning transplant was a sig-
nificant predictor of higher score in the
three dimensions (physical functioning,
vitality, and mental health) for which
multiple regression models were con-
structed. Age, sex, comorbidity, duration
of treatment, level of social and emotional
support, household numbers, and hospital
dialysis were also (variably) significant
predictors.
Conclusions—The SF36 is a practical and
consistent questionnaire in this context,
and there is evidence to support its
construct validity. Overall the health re-
lated quality of life of these patients is
poor, although transplantation is associ-
ated with higher scores independently of
the eVect of age and comorbidity. Age,
comorbidity, and sex are also predictive of
the scores attained in the three dimen-
sions studied. Further studies are re-
quired to ascertain whether altering those
predictor variables which are under the
influence of professional carers is associ-
ated with changes in health related quality
of life, and thus confirm the value of this
outcome as a measure of quality of care.
(Quality in Health Care 1998;7:209–221)
Keywords: end stage renal failure; health related quality
of life; short form 36
Introduction
MEASURING HEALTH RELATED QUALITY OF LIFE
IN END STAGE RENAL FAILURE
Although treatments for end stage renal failure
are undoubtedly eVective in preventing death,
clinicians and commissioning authorities are
increasingly concerned to monitor other rel-
evant outcomes of treatment as measures of the
quality of care provided. The advice currently
available1 2 focuses on laboratory measure-
ments of biological variables that are aVected
by the dialysis process, reflecting the techno-
logical nature of the treatment. Patient per-
ceived health related quality of life is another
outcome which is of particular interest for sev-
eral reasons.
The formal assessment of the health related
quality of life of dialysis patients may bring
several benefits. For patients, it may bring to
light problems that are amenable to interven-
tion.3 For providers, the recognition that health
related quality of life is aVected by mode and
place of treatment, or other factors may lead to
changes in policy about treatment. For both
health service commissioners and providers
information about the eVect of age or comor-
bidity on health related quality of life may pro-
vide valuable information for diYcult decisions
about the level of investment in the service.
Secondly, treatment for end stage renal fail-
ure is very expensive, and will consume an
increasing proportion of the healthcare budget
as the numbers of patients taken on to
treatment programmes continues to exceed the
death rate of those on treatment. In an era of
constrained resources, this raises questions as
to how the outcomes of these treatments com-
pare with alternative health interventions. To
make such comparisons, we need tools to
measure outcomes common to all. Quality of
life related to general health as assessed by the
patient is one such outcome.
Assessment of health related quality of life
indicates quality of care to the extent that the
care provided influences quality of life. We
need, therefore, first to identify a questionnaire
for the measurement of health related quality
of life, and then to examine the determinants of
health related quality of life as measured by
that questionnaire, and establish whether or
not they relate to the quality of care provided.
This study evaluates the short form 36 (SF36)
as a measure of the health related quality of life
of patients with end stage renal failure. It will
be of interest both to those who are concerned
with the technical aspects of the SF36 itself, as
well as renal physicians and others who are
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concerned to document the health related
quality of life of these patients.
The only person truly qualified to assess a
patient’s health related quality of life is the
patient. Studies in which doctors’, nurses’ and
patients’ assessments have been compared have
shown substantial disagreement between
them.4–6
CHOICE OF QUESTIONNAIRE
Many of the questionnaires used to assess
health related quality of life in patients with end
stage renal failure in the past7 have the
disadvantages of being too long for routine use
or not having been well validated. The disease
specific questionnaires that have been
developed8–12 have not been well validated in
large samples, and do not give results that can
be compared with the general disease free
population, or other patient groups. Given that
the objective of treatment for end stage renal
failure is to replace renal function as com-
pletely as possible, it is appropriate to use a
questionnaire that is designed to measure vari-
ations in the health status of normal people. A
more general questionnaire has the further
advantage, at least in theory, of being sensitive
to the eVect of comorbidity.
SF36 QUESTIONNAIRE
The SF36 questionnaire is one such measure.13
In it, the data from 36 questions are combined
to provide a measure of health related quality of
life in eight dimensions. These are: physical
functioning (PF), role limitations attributable
to physical problems (RP), bodily pain (BP),
perception of general health (GH), vitality
(VIT), social functioning (SF), role limitations
attributable to emotional problems (RE), and
mental health (MH). A score from 0 (lowest
health related quality of life) to 100 (highest) is
derived for each.
Its reliability and validity have been well
assessed14 15 and normative data exist for the
general English population.15 16 It has also been
shown to be valid and acceptable to patients
<65 years.17–19 Although it is increasingly being
used as an outcome measure for patients with
end stage renal failure3 20–23 it has not been for-
mally assessed in this population.24
ASSESSING THE USE OF THE SF36
The assessment of the use of the SF36 in the
population with end stage renal failure involves
seeking answers to several questions:
x Is the questionnaire practical in terms of
achieving an adequate response rate?
x Does the questionnaire have internal
consistency when used in this popula-
tion?
x Are there large proportions of responses
being either at the minimum or maxi-
mum values possible, rendering the
questionnaire useless as a discriminatory
tool (floor or ceiling eVects)?
x Does the questionnaire have construct
validity in this population?
x How comprehensive is the questionnaire
in reflecting all the aspects of health
related quality of life which are impor-
tant to these patients?
To assess the comprehensiveness of a general
questionnaire in a specific context, it is
necessary to establish whether there are other
important aspects of health related quality of
life which it does not cover, and which may
vary independently of those aspects which are
covered. This requires asking additional ques-
tions relating specifically to the symptoms of
end stage renal failure, and then determining
the extent to which the information gathered is
independent of the results of the SF36. One
way to determine this is to examine the corre-
lation between the SF36 results and the
responses to the specific questions on end stage
renal failure.
A high correlation suggests that those
patients who have a poor health related quality
of life, as measured by the SF36, also have a
quality of life which is impaired by specific
symptoms of end stage renal failure, and vice
versa—those whose health related quality of
life as measured by the SF36 is high do not
have severe symptoms of end stage renal
failure. A low correlation suggests the
opposite—that the severity of symptoms of end
stage renal failure may be independent of
health related quality of life measured by the
SF36. If that were to be the case, the additional
specific questions about end stage renal failure
could give useful additional information. The
supplementation of general questionnaires
with disease specific questions has been
advocated elsewhere.25
STUDY OBJECTIVES
The purpose of the work described here was:
x To evaluate the use of the SF36 by
patients with end stage renal failure
x To document the health related quality
of life (as measured by the SF36) of
patients with end stage renal failure
being treated at the SheYeld Kidney
Institute
x To investigate factors, including treat-
ment, which may influence the health
related quality of life of these patients.
It was decided to investigate the use of the
SF36 in patients undergoing all modes of
treatment (home, hospital, and satellite unit
haemodialysis, peritoneal dialysis, and trans-
plantation) because the questionnaire may per-
form diVerently in diVerent groups of patients.
Furthermore, a comparison of the results
between treatments would contribute towards
establishing the construct validity of the
questionnaire, and thus be of independent
interest.
Patients and methods
The study was conducted in the SheYeld Kid-
ney Institute at the Northern General Hospital,
SheYeld, from April to June of 1995. The pro-
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tocol was approved by the local research ethics
committee. The cooperation of the SheYeld
Kidney Patients Association was sought and
obtained.
Sample size calculations showed that to have
an 80% chance of detecting a 10 point
diVerence in score between treatments with a
significance level of 5%, it would be necessary
to have between 52 and 183 patients in each
group, depending on the dimension.26 It was
therefore decided to study all 660 patients
being treated at the time.
A questionnaire was prepared consisting of
the standard United Kingdom version of the
SF36, supplemented by eight questions about
specific symptoms of end stage renal failure.
The symptoms were chosen because they had
been reported by patients to be important and
because the clinicians concurred with this, and
they had been incorporated by others into dis-
ease specific questionnaires.11 27 28 The eight
symptoms were: dry or itchy skin; cramps; dif-
ficulty sleeping; thirst; problems with access
site; muscle wasting; nausea; and impairment
of sex drive. To assess the extent to which the
symptom aVected quality of life, and not
simply record its presence, the questions were
phrased “during the past 4 weeks how much
have you been bothered by ...”. Respondents
were asked to indicate the extent on a scale
from 1 (not at all) to 6 (extremely). These
questions were designed for this study, and had
not been independently validated. The full
questionnaire is included as an appendix.
An information sheet was provided for each
patient. Completion of the questionnaire was
taken as a patient’s consent to participation.
(This approach is endorsed by the Royal
College of Physicians in its guidelines to local
research ethics committees.)
DATA COLLECTION
As one of the aims of the study was to evaluate
the use of the SF36 in measuring overall health
related quality of life, care was taken to ensure
that patients did not complete the question-
naire while undergoing dialysis, which can be a
distressing experience. Furthermore, the reli-
ability of quality of life measures may be greater
if they are completed between, rather than dur-
ing, dialysis treatments.29
The questionnaires were distributed by hand
to hospital haemodialysis patients, with a
request that they should be completed at home
between treatments. They were posted, with a
stamped addressed envelope, to all other
patients. One reminder was sent after 4 weeks.
All other data, including age, comorbidity,
adequacy of dialysis (as measured by urea
kinetic modelling), and haematological and
biochemical variables, were obtained from
hospital records. A risk category was deter-
mined for each patient according to previously
published criteria.30 This categorises patients
according to age and the presence of important
cardiac, respiratory, or other organ disease,
diabetes, or malignancy. (The categorisation
was as follows: group 1 (low risk) age <70, no
concurrent illness; group 2 (medium risk) age
70–9, or diabetic, or notable cardiac or pulmo-
nary disease; group 3 (high risk) age >80, or
diabetes with age >70, or dysfunction of >2
organs as well as end stage renal failure, or
malignancy (excluding skin cancers).) The risk
categories have been shown to be significant
predictors of survival in patients with end stage
renal failure. Comparisons were made with age
and sex matched controls from the general
population of SheYeld, using data collected for
a previous study.15 Age (within 5 year age
bands) and sex matched cases were chosen at
random.
STATISTICAL ANALYSIS
Data were entered on to a personal computer.
Statistical tests were performed with SPSS for
Windows. Because of the non-normal distribu-
tion of most of the data, the Kruskal-Wallis test
was used when comparing the dimension
scores between treatments, and the Wilcoxon
matched pairs signed ranks test when compar-
ing the scores of patients and age and sex
matched controls. To compare patients and
controls the eVect size (the diVerence between
means divided by the SD of the control group)
was calculated for each dimension (this has the
advantage of showing the size of the signal (the
diVerence in scores) in comparison with the
noise (the variability in score—that is, the SD).
By convention, an eVect size of 0.2–0.5 is
small, 0.5–0.8 moderate, and >0.8 is large.31
The scoring of the questions specific to the
condition (1–6) was reversed so that lower
scores indicated a more severely impaired
quality of life, to be consistent with the SF36
dimension scores. To measure the correlations
between them, both sets of data were treated as
ordinal, and the correlation measured with the
Kendall’s tau-b coeYcient.
The relation between independent factors
and health related quality of life was explored
by looking at the correlations between variables
and the SF36 dimension scores, and by multi-
ple regression analysis. Firstly the Spearman
rank correlation coeYcients for cross correla-
tion between the individual dimensions of the
SF36, correlations between the independent
variables and the individual dimension scores,
and cross correlation between the independent
variables, were calculated.
Any obvious non-linear relations were then
sought by examining scatterplots of the indi-
vidual dimension scores and the independent
variables. None were detected. Multiple
regression models were then constructed. To
reduce the likelihood of spurious significant
relations being discovered (type 1 errors), and
because the diVerent dimensions of functioning
were highly correlated with each other, as were
the wellbeing dimensions, further analysis was
restricted to the three dimensions physical func-
tioning, vitality, and mental health. Dummy
variables were created for each type of treat-
ment, sex, and history of previous transplanta-
tion. Missing data were deleted from the list, and
the entry of variables into the model was deter-
mined stepwise, with a p value for entry of 0.05
and for removal of 0.1. Residuals were examined
for normality and the absence of any trend in
value (the prime assumptions for multiple
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regression). In every model these assumptions
were met.
The higher SF36 scores for patients who had
had a transplant compared with those who had
had dialysis raised the possibility that the
determinants of their quality of life are
diVerent. Three sets of multiple regression
models were constructed, one for all patients
combined, one for patients on dialysis, and one
for transplanted patients only.
Results
CHARACTERISTICS OF THE POPULATION AND
RESPONSE RATES
From the 660 patients surveyed, 520 responses
(78.8%) were returned. There was no diVer-
ence in response rate between treatments, sex,
or district of residence. Nor was there any dif-
ference in the age, duration of treatment, or
distance travelled to treatment between re-
sponders and non-responders. Fewer than 2%
of patients required assistance in completing
the questionnaire, assistance which was pro-
vided by an experienced dialysis nurse re-
cruited for the study.
Ethnic minorities make up about 5% of the
patients treated at the SheYeld Kidney Insti-
tute. Ethnicity was therefore not analysed
further. The characteristics of the patients
studied are given in table 1.
EVALUATION OF THE USE OF THE SF36 IN
PATIENTS WITH END STAGE RENAL FAILURE
Acceptability of the questionnaire
The high response rate, and informal com-
ments from patients, gives an indication, albeit
limited, that the questionnaire was acceptable
to most of them. Some commented that it took
longer than the estimated 10–15 minutes to
complete.
Internal consistency
Cronbach’s á was >0.8 for each dimension
except social functioning, for which the overall
value was 0.72 (table 2). In this dimension it
was 0.79 for transplanted patients, and 0.60 for
dialysis patients.
Floor and ceiling eVects
The percentage of minimal (a score of 0, floor)
or maximal responses (a score of 100, ceiling)
are also shown in table 2. For all except the
“role physical” and “role emotional” dimen-
sions responses are spread across the range of
possible results. Similar results were obtained
when each treatment was examined separately
(data not shown).
Comprehensiveness
The distribution of responses (for all patients
combined) to the specific questions about end
stage renal failure was in each case heavily
Table 1 Demographic data (n (%))
Total Home Hosp PD Sat Tx
Sex:
Male 312 (60) 29 (69.0) 56 (56.0) 62 (56.9) 24 (58.5) 141 (61.8)
Female 208 (40) 13 (31.0) 44 (44.0) 47 (43.1) 17 (41.5) 87 (38.2)
Total 520 42 100 109 41 228
Age (y):
<19 5 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 5 (2.2)
20–29 39 (7.5) 4 (9.5) 4 (4.0) 6 (5.5) 2 (4.9) 23 (10.1)
30–39 84 (16.2) 9 (21.4) 13 (13.0) 15 (13.8) 5 (12.2) 42 (18.4)
40–49 92 (17.7) 9 (21.4) 15 (15.0) 15 (13.8) 2 (4.9) 51 (22.4)
50–59 135 (26.0) 16 (38.1) 23 (23.0) 27 (24.8) 10 (24.4) 59 (25.9)
60–69 113 (21.7) 4 (9.5) 28 (28.0) 27 (24.8) 12 (29.3) 42 (18.4)
70–79 49 (9.4) 0 (0.0) 17 (17.0) 18 (16.5) 9 (22.0) 5 (2.2)
>80 3 (0.6) 0 (0.0) 0 (0.0) 1 (0.9) 1 (2.4) 1 (0.4)
Total 520 42 100 109 41 228
Duration of treatment (y):
0–4 250 (48.1) 13 (31.0) 66 (66.0) 92 (84.4) 25 (61.0) 64 (28.1)
5–9 124 (23.8) 13 (31.0) 20 (20.0) 10 (9.2) 10 (24.4) 71 (31.1)
10–14 66 (12.7) 9 (21.4) 9 (9.0) 5 (4.6) 4 (9.8) 39 (17.1)
15–19 40 (7.7) 4 (9.5) 4 (4.0) 0 (0.0) 1 (2.4) 31 (13.6)
20–24 22 (4.2) 2 (4.8) 0 (0.0) 1 (0.9) 1 (2.4) 18 (7.9)
25–29 8 (1.5) 1 (2.4) 1 (1.0) 1 (0.9) 0 (0.0) 5 (2.2)
Total 520 42 100 109 41 228
Comorbidity:
Diabetes 66 (12.7) 0 (0.0) 11 (11.0) 24 (22.0) 8 (19.5) 23 (10.1)
Cardiac and pulmonary
disease
115 (22.1) 9 (21.4) 30 (30.0) 28 (25.7) 13 (31.7) 35 (15.4)
Other organ failure 1 (0.2) 0 (0.0) 1 (1.0) 0 (0.0) 0 (0.0) 0 (0.0)
Malignancy 15 (2.9) 0 (0.0) 4 (4.0) 7 (6.4) 0 (0.0) 4 (1.8)
Home=home haemodialysis patients; Hosp=hospital haemodialysis patients; PD=peritoneal dialysis patients; Sat=satellite haemo-
dialysis patients; Tx=transplanted patients.
Table 2 Dimensions of quality of life
Physical
function
Role
physical
Bodily
pain
General
health Vitality
Social
functioning
Role
emotional
Mental
health
Subjects (n) 514 492 517 499 517 518 489 514
Cronbach’s á 0.95 0.93 0.91 0.83 0.86 0.72 0.90 0.82
Median 45 0 66.7 40 45 55.6 66.7 71.3
Interquartile range 20–80 00–100 33.3–100 22–62 25–60 33.3–88.9 0–100 55.3–84.0
Responses at lowest
possible score (%)
4.9 50.8 3.5 1.8 4.5 5.4 34.4 0.4
Responses at highest
possible score (%)
6.8 28.7 26.5 2.0 0.8 22.9 47.0 4.7
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skewed towards the higher scores. Thus it is
clear that the symptoms asked about did not
interfere greatly with the quality of life of the
most patients. However, when the responses of
dialysis and transplanted patients are analysed
separately, as shown in the figure, the responses
for dialysis patients are less skewed towards
higher scores for the questions relating to dry
skin, cramps, diYculty sleeping, and thirst.
This suggests that for these patients, these par-
ticular questions do discriminate between
some patients for whom these symptoms do
interfere with their quality of life, and others for
whom this is not the case.
Distribution of responses to specific questions about end stage renal failure by dialysis and transplanted patients. The
response categories 1–6 indicate increasing impairment of quality of life by the symptom. Each diagram shows the number
of patients returning that response for that symptom.
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As a test of whether the extra questions were
giving useful extra information about the
health related quality of life of these patients,
the correlation coeYcients between the SF36
dimension scores and the responses to the extra
questions were calculated. When all patients
were included, correlations overall were mod-
erate. The greatest correlation was between the
social functioning dimension and thirst (Kend-
all’s tau-b=0.38), and the least between the
mental health dimension and impairment of
sex drive (tau-b=0.18).
Because the skew in responses to these ques-
tions was largely attributable to the trans-
planted patients, correlation coeYcients were
calculated for dialysis and transplanted pa-
tients separately. For transplanted patients the
coeYcients were still moderate, ranging from
0.38 (social functioning and diYculty sleeping)
to 0.11 (role emotional and access). However,
for dialysis patients the coeYcients were lower,
the greatest being 0.30, between bodily pain
and diYculty sleeping. In 10 cases the
significance of the correlation was <0.01
(p>0.01).
The fact that there was less correlation
between the responses to extra questions and
the SF36 dimensions for dialysis than for
transplanted patients indicates that, in these
patients, the additional questions were more
useful in detecting extra information, and by
inference the SF36 was less comprehensive.
HEALTH RELATED QUALITY OF LIFE OF PATIENTS
WITH END STAGE RENAL FAILURE
The mean scores for each SF36 dimension for
all patients and each treatment group, together
with scores of the age and sex matched
controls, and the diVerences between each
treatment group and age and sex matched con-
trols as measured by the eVect sizes, are shown
in table 3. The mean scores for all patients with
end stage renal failure combined were lower
than the control group on every dimension.
Transplanted patients scored higher than
other treatment groups on every dimension, but
not as high as control patients. Patients on hos-
pital and satellite haemodialysis tended to score
lower than those on peritoneal dialysis or home
haemodialysis patients. The diVerences between
treatments were highly significant for all eight
dimensions (Kruskal-Wallis p<0.0001). When
transplanted patients were excluded the diVer-
ences between remaining treatments were sig-
nificant (p<0.01) only for the physical function-
ing, role physical, social functioning and role
emotional dimensions. (In the other dimen-
sions, the diVerence in scores was <10.4 points.
Given the size of the subgroups, the study did
not have the power to detect diVerences of this
magnitude.)
EVect sizes for the patients on dialysis were
large for all except the mental health dimension
(all dialysis modalities), role emotional in home
dialysis patients, and bodily pain in the perito-
neal and satellite dialysis patients. For the
Table 3 Mean (SD) score for each dimension for all patients and each treatment group, together with the scores for the
relevant age and sex matched control group, the eVect size, and the p value for the diVerence between patients and age and
sex matched controls with the Wilcoxon matched pairs signed ranks test
Mean
Physical
function
Role
physical
Bodily
pain
General
health Vitality
Social
functioning
Role
emotional
Mental
health
All:
Mean 48.5 37.4 61.3 42.9 43.4 60.4 56.0 68.3
Control 82.2 78.8 77.5 69.5 58.4 88.0 82.5 74.2
SD (control) 23.6 35.8 24.3 21.6 13.0 21.4 33.2 19.1
EVect size 1.43 1.16 0.67 1.23 1.15 1.29 0.80 0.31
p Value
Home:
Mean 47.1 40.9 54.7 38.1 41.7 62.9 65.0 68.8
Control 86.3 84.8 80.8 74.4 61.6 87.3 82.9 76.6
SD (control) 22.3 31.6 25.1 24.0 10.7 24.8 34.3 18.7
EVect size 1.75 1.39 1.04 1.51 1.86 0.98 0.52 0.42
p Value 0.0006 0.0001 0.0007 0.0630 0.1318
Hosp:
Mean 33.6 23.6 48.6 31.6 34.5 41.9 31.0 60.0
Control 79.3 74.2 76.9 67.0 56.3 85.8 76.4 73.0
SD (control) 24.5 38.0 23.9 21.4 13.2 23.2 36.8 18.3
EVect Size 1.86 1.33 1.19 1.66 1.65 1.89 1.23 0.71
p Value
PD:
Mean 40.6 20.4 59.0 35.1 35.8 50.0 55.5 65.9
Control 81.5 81.4 76.4 70.9 59.3 90.3 83.8 75.6
SD (control) 23.7 34.6 24.5 21.3 12.2 28.8 32.6 18.3
EVect size 1.73 1.76 0.71 1.68 1.93 1.40 0.87 0.53
p Value 0.0004
Sat:
Mean 28.3 16.7 55.3 31.6 32.0 48.8 29.7 66.6
Control 74.4 67.9 73.3 64.5 61.7 85.9 87.0 77.9
SD (control) 28.8 42.3 26.7 21.9 14.6 22.1 31.2 15.8
EVect size 1.60 1.21 0.68 1.50 2.04 1.68 1.84 0.71
p Value 0.0002 0.0080 0.0001 0.0026
Tx:
Mean 62.5 53.5 70.2 54.3 53.2 75.2 68.8 73.2
Control 84.4 80.1 78.4 69.8 57.7 88.5 83.4 73.0
SD (control) 22.2 34.8 23.8 21.3 13.3 21.4 32.0 20.4
EVect size 0.99 0.76 0.34 0.73 0.33 0.62 0.46 −0.01
p Value 0.0031 0.0597 0.6959
Where the p value is not given it is <0.0001.
Home=home haemodialysis patients; Hosp=hospital haemodialysis patients; PD=peritoneal dialysis patients; Sat=satellite haemo-
dialysis patients; Tx=transplanted patients.
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transplanted patients, eVect sizes were small or
moderate for all except the physical functioning
dimension. The p value for the diVerences in
dimension scores between treatment and
control groups were <0.01 (Wilcoxon matched
pairs signed ranks test) for all except vitality
and mental health scores in the transplanted
patients, and role emotional and mental health
in the patients on home dialysis.
RELATION BETWEEN INDEPENDENT VARIABLES,
INCLUDING TREATMENTS, AND SF36 SCORES
A high correlation was found between the
dimension scores. Specifically, the diVerent
physical dimensions were highly correlated
with each other (physical functioning v role
physical, rs=0.61), as were the mental/emot-
ional dimensions (mental health v role emo-
tional, rs=0.52). However, correlation between
physical and mental dimensions was less
(physical functioning v mental health, rs=0.35).
Details of correlations between independent
variables and the dimensions of the SF36 are
given in table 4. There was no correlation
between dimension scores and: household
numbers, previous transplantation, distance
travelled, district of residence, adequacy of
dialysis, and biochemical measures other than
serum albumin and total protein (serum
sodium, potassium, bicarbonate, creatinine,
urea, phosphate, calcium, and alkaline phos-
phatae).
Some of the independent variables (as
expected) were highly correlated with one
another, in particular, distance travelled and
travel time (rs=0.95), and serum albumin and
total protein levels (rs=0.80).
MULTIPLE REGRESSION MODELS
The models may be summarised as formulas as
shown in the box. Independent variables
appear in each formula in order of significance.
Variables that do not appear were not signifi-
cantly associated with that dimension score in
that model. Full details of model characteris-
tics are shown in table 5.
Discussion
EVALUATION OF THE USE OF THE SF36
Although the SF36 is increasingly being used
in patients treated for end stage renal
failure,3 20–23 its use in this population has not
previously been formally assessed.
Models may be summarised as follows:
FOR ALL PATIENTS
Physical functioning = 97 − 0.75 (age) + 19.57 (transplant) − 10.87 (female) − 7.62 (risk) −
0.04 (duration)
Vitality = 39 + 8.90 (transplant) − 0.33 (age) + 1.59 (Hb) − 4.57 (risk) +1.87 (social and
emotional support) − 1.43 (household numbers)
Mental health = 60 + 4.72 (transplant) +2.79 (social and emotional support) − 6.57 (hospital)
− 4.57 (female) − 2.86 (risk)
FOR PATIENTS ON DIALYSIS ONLY
Physical functioning = 80 − 0.41 (age) − 11.37 (female) − 8.44 (risk) − 0.10 (travel time)
Vitality = 33 − 6.27 (risk) - 5.64 (female) + 1.43 (Hb)
Mental health = 30 − 6.89 (hospital dialysis) +2.14 (social and emotional support) + 0.50
(albumin)
FOR TRANSPLANTED PATIENTS ONLY
Physical functioning = 98 − 1.28 (age) − 8.80 (female) − 2.09 (Hb)
Vitality = −3.8 − 0.60 (age) +3.60 (social and emotional support) + 1.69 (Hb) + 0.61 (total
protein)
Mental health = 52 + 4.14 (social and emotional support) Where: age = age (y); transplant = 1
for transplant patients, 0 for others; female = 1 for women, 0 for men; risk = risk category30;
duration = duration of treatment (y); Hb = haemoglobin in g/dl; hospital dialysis = 1 for patients
on hospital dialysis, 0 for all others; travel time = travel time in minutes; Albumin = serum albu-
min in g/l; total protein = serum total protein in g/l.
Table 4 Spearman rank correlation coeYcients between independent variables and the individual dimension scores
Age (y) Risk score Duration Distance Travel time
Social and
emotional
support Haemoglobin Albumin
Total
protein Sex
Physical functioning −0.46 −0.36 0.11 −0.31 −0.29 0.05 0.33 0.29 0.26 −0.19
Role physical −0.31 −0.29 0.18 −0.24 −0.24 0.05 0.28 0.28 0.23 −0.05
Bodily pain −0.20 −0.15 −0.01 −0.20 −0.19 0.09 0.22 0.19 0.19 −0.06
General health −0.16 −0.24 0.10 −0.27 −0.26 0.15 0.38 0.30 0.24 −0.07
Vitality −0.27 −0.23 0.13 −0.24 −0.23 0.02 0.32 0.28 0.25 −0.10
Social functioning −0.23 −0.28 −0.21 −0.31 −0.30 0.11 0.33 0.31 0.26 −0.09
Role emotional −0.24 −0.20 −0.17 −0.31 −0.30 0.20 0.18 0.19 0.17 −0.04
Mental health −0.05 −0.12 0.10 −0.20 −0.17 0.23 0.21 0.15 0.16 −0.11
Risk=risk category (see text); Duration=duration of end stage renal failure treatment (y); Distance=distance travelled for treatment; Travel time=time taken to travel
for treatment; Social and emotional support=self assessed level of social and emotional support; Albumin=serum albumin; Total protein=serum total protein.
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A high response rate was obtained. Internal
consistency was shown by values of Cronbach’s
á >0.8 for seven of the eight dimensions. It is
possible that the low figure for the social func-
tioning dimension arises as a result of the
patients’ health providing the rationale for such
social activities as they have on the dialysis unit.
The lower value for dialysis than transplant
patients supports this supposition.
There are no floor or ceiling eVects, other
than for the role dimensions. This has been
reported previously in renal patients,3 20 and in
general populations,15 and so may indicate an
inherent flaw in the questionnaire. These
dimensions derive from questions about
“problems with work or other regular daily
activities”, which may not be appropriate for
chronically ill people, or elderly people,18 who
are unlikely to be in work.
Evidence of construct validity comes from
the comparison of scores with those of a
general population, and the better scores
obtained by transplant patients. The lower cor-
relation between the SF36 dimension scores
and the responses to the additional specific
questions about renal failure in dialysis patients
suggests that there are domains of health
related quality of life that are important in
these patients, and which may not be covered
by the questionnaire.
HEALTH RELATED QUALITY OF LIFE OF PATIENTS
BEING TREATED FOR END STAGE RENAL FAILURE
Overall, scores do not compare well with the
general population. The diVerence between the
patients on dialysis and controls varies, but aver-
ages over 30 points—which is greater than the
diVerence between 65–74 year olds and 25–34
year olds in the general population.15 (Most of
the p values for these comparisons are <0.0001,
rendering the likelihood of type 1 errors—
attributing a real diVerence where none exists—
extremely unlikely.) EVect sizes were smaller for
the mental than physical dimensions (as in the
only other study to quote eVect sizes23), and
there was also less diVerence in scores between
treatments in these dimensions.
Comparisons may also be made with other
chronic conditions.32 These patients had better
scores for vitality and mental health, and simi-
lar scores for physical functioning, compared
with a group of patients with low back pain.
They also scored higher in mental health and
vitality than patients with menorrhagia and
higher in mental health than patients with sus-
pected peptic ulcer. Patients with varicose veins
scored higher in all these dimensions.
RELATION BETWEEN TREATMENT AND INDIVIDUAL
DIMENSION SCORES
The presence of a functioning transplant
remained a significant predictor of improved
health related quality of life scores, even when
age, haemoglobin, and comorbidity (risk score)
were taken into account in the multiple
regression models. As transplantation obviates
the need for dialysis, this is not a surprising
finding, and is in keeping with other studies.33–39
Hospital dialysis was significantly negatively
associated with mental health score, even when
other predictive factors were taken into ac-
count. It is not possible to say from this study
whether there is a causal relation between hos-
pital dialysis and poor mental health score, nor
the direction of any causation. However
patients on hospital dialysis, of all the groups
studied, have the least control over their own
treatment, which may contribute to the lower
score.40–43
None of the other three treatments (home
dialysis, satellite dialysis, and peritoneal dialy-
sis) were significant predictors of the scores.
Thus, any diVerences between these groups
are explained by the diVerent case mix. This
finding diVers from that of some other
investigators.36 44
OTHER PREDICTIVE FACTORS
Age emerges as the most important predictor
of physical functioning score for all patients, as
well as when dialysis and transplant patients
were analysed separately. It is also a predictor
of vitality score in transplanted patients and in
patients as a whole, but not when the analysis is
restricted to dialysis patients. It is not a predic-
tive factor for the mental health scores in either
subgroup or in all patients—indicating that
there is no reduction in mental health score
with age. All these observations, including the
magnitude of decline in physical functioning
Table 5 Summary of values of B (standard error of B) for predictive variables and model characteristics for the multiple regression models
Variables in the equation
Dependent variable
Physical functioning Vitality Mental health
All patients Dialysis only Transplants All patients Dialysis only Transplants All patients Dialysis only Transplants
Age (y) −0.75 (0.09) −0.41 (0.12) −1.27 (0.13) −0.33 (0.08) −0.60 (0.11)
Transplant 19.57 (2.64) 8.90 (2.68) 4.72 (1.96)
Sex −10.87 (2.40) −11.37 (3.11) −9.80 (3.79) −5.64 (2.55) −4.57 (1.75)
Haemoglobin 2.09 (0.94) 1.59 (0.53) 1.43 (0.71) 1.69 (0.79)
Risk −7.62 (2.06) −8.44 (2.52) −4.57 (1.75) −6.27 (1.88) −2.86 (1.39)
Hospital dialysis −6.57 (2.43) −6.89 (2.42)
Social and emotional
support
1.87 (0.76) 3.60 (1.27) 2.79 (0.65) 2.14 (0.83) 4.14 (1.07)
Household number −1.91 (0.79)
Albumin 0.50 (0.21)
Total protein 0.61 (0.30)
Travel time −0.10 (0.05)
Duration −0.04 (0.02)
Adjusted R2 0.33 0.17 0.31 0.19 0.06 0.16 0.10 0.05 0.06
F 52.03 15.27 35.44 21.22 7.38 11.63 12.60 6.36 14.90
Significanee of F <0.0001 <0.0001 <0.0001 <0.0001 =0.0001 <0.0001 <0.0001 =0.0003 =0.0001
n 520 292 228 520 292 228 520 292 228
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score with age, are similar to findings in the
general population.15 Thus, other things being
equal, and in particular in the absence of nota-
ble comorbidity, there is no greater decline in
health related quality of life of patients with end
stage renal failure than in the general popula-
tion. Further, the independence of mental
health score from age suggests that older
patients with end stage renal failure are just as
well adjusted psychologically as younger ones.
These findings will lend further weight to
demands that more older people merit dialysis.
Sex is a significant predictor of physical
functioning in both subgroups and in all
patients. It is also a predictor of vitality in
dialysis patients, and mental health score for all
patients, (but not for each subgroup). (In all
cases men scored higher than women.) The
diVerence in physical functioning score be-
tween sexes is greater in these patients than in
the normal 55–64 year age group.15 We can
only speculate as to the reasons for this. It may
be that whereas men on renal replacement
therapy are cared for by their wives or other
family members, women are less supported,
and further may not themselves perform the
normal female supportive roles. This merits
further research.
Risk score was a significant predictor for
physical functioning and vitality in patients on
dialysis, and for all three treatments when all
patients were combined. This is not surprising
in view of the way risk categories are
determined.30 It adds value to this simple scor-
ing system, which predicts mortality in patients
with end stage renal failure both before45 and
after30 46 starting dialysis. However, many pa-
tients had other comorbidities not included
within this score, which will have contributed
to the residual variance. It was not a predictor
in the transplanted patients. Self assessed social
and emotional support was a significant
predictor of vitality score (transplanted pa-
tients and all patients) and mental health score
(both subgroups and all patients).
It would be unwise to overinterpret the other
independent variables that are predictive in
single models, given the multiple comparisons
that have been made. The fact that haemo-
globin concentration does not seem to be a
good predictor of SF36 score in the multiple
regression models (other than for vitality, and
even there the eVect is modest), is perhaps sur-
prising, in view of the documented eVect of
erythropoietin induced increases in haemo-
globin on quality of life.47 48 This may be
explained by the fact that many of the patients
studied were being treated with erythropoietin,
so that the haemoglobin concentrations did not
vary greatly.
Adequacy of dialysis was not related to qual-
ity of life scores, a finding that replicates other
studies.23 49 50 Similarly, distance from the treat-
ment centre, history of transplantation,51 mari-
tal status,8 10 and district of residence did not
bear any relation to any of the three dimensions
of quality of life examined.
The overall predictive power of these models
was modest. The model with physical function-
ing as the dependent variable, with all patients,
achieved the highest adjusted R2, and even in
this case it was only 0.33, indicating that only
just 33% of the variability in score was
explained by the independent variables exam-
ined. For the other dimensions, in particular
the mental health score, the figure was much
less, indicating that <10% of the variability
could be explained by the model. These
findings are similar to those of another study in
which the links between various predictive fac-
tors and SF36 scores were explored.23
Conclusions
The SF36 is a practical and consistent
questionnaire for measuring the health related
quality of life of transplanted and dialysis
patients, although some caution is needed in
interpreting the scores of emotional and physi-
cal roles. There is support for its validity. How-
ever there are domains of health related quality
of life of these patients, particularly those on
dialysis, which are not assessed by this
questionnaire.
Overall, the results indicate that health
related quality of life is poor, and worse in
physical than in mental and emotional dimen-
sions. Improved scores achieved by trans-
planted patients persist even when other possi-
ble explanatory variables are taken into
account. Health related quality of life is no
more aVected by age in the population with
end stage renal failure than in the general
population, but the quality of life enjoyed by
female patients does seem to be worse than that
of male patients. The level of comorbidity
remains an important predictor.
Health related quality of life reflects quality
of care to the extent that factors which
influence quality of life are amenable to
intervention by professional carers. The ob-
served correlations reported here cannot be
taken to indicate causality. That can only be
shown by intervention studies—for example
providing increased levels of social support to
determine whether this aVects the mental
health score. These findings should help to
inform the designers of such studies, and so
eventually lead to improved quality of care and
quality of life for patients with end stage renal
failure.
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